Mesoblast (MESO) Non-Current Debt (2018 - 2025)
Mesoblast's (MESO) quarterly Non-Current Debt came in at -$149.3 million in Q4 2025, down 7.0% year-on-year from -$160.6 million in Q4 2024, and down 192.43% quarter-over-quarter from $161.6 million in Q2 2025.
Mesoblast (MESO) Non-Current Debt (2018 - 2025) Analysis & Trends
Mesoblast has disclosed Non-Current Debt across 8 years of filings, most recently posting -$149.3 million for Q4 2025.
- Non-Current Debt for Q4 2025 came in at -$149.3 million, down 7.0% year-over-year; the trailing twelve-month figure through Dec 2025 was -$149.3 million (down 7.0% YoY), and the FY2025 annual result was $161.6 million, up 60.77% from the prior year.
- Non-Current Debt came in at -$149.3 million for Q4 2025 at Mesoblast, down from $161.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $161.6 million in Q2 2025 to a low of -$149.3 million in Q4 2025.
- The 5-year median for Non-Current Debt is -$37.3 million (2021), against an average of -$14.9 million.
- Across the five-year window, Non-Current Debt retreated 28.02% in 2021 and surged 123.21% in 2022, its largest moves.
- Mesoblast's Non-Current Debt stood at $41.0 million in 2021, then tumbled by 381.92% to -$115.7 million in 2022, then fell by 6.29% to -$123.0 million in 2023, then slipped by 13.46% to -$139.5 million in 2024, then declined by 7.0% to -$149.3 million in 2025.
- The last three Non-Current Debt figures came in at -$149.3 million (Q4 2025), $161.6 million (Q2 2025), and -$139.5 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | -149.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -149.32 Mn |
| Dec 31, 2025 | -149.32 Mn |
| Jun 30, 2025 | 161.55 Mn |
| Jun 30, 2025 | 161.55 Mn |
| Dec 31, 2024 | -139.55 Mn |
| Dec 31, 2024 | -139.55 Mn |
| Jun 30, 2024 | 100.48 Mn |
| Jun 30, 2024 | 100.48 Mn |
| Dec 31, 2023 | -122.99 Mn |
| Dec 31, 2023 | -122.99 Mn |
| Jun 30, 2023 | 102.81 Mn |
| Jun 30, 2023 | 102.81 Mn |
| Mar 31, 2023 | -119.06 Mn |
| Mar 31, 2023 | -119.06 Mn |
| Dec 31, 2022 | -115.72 Mn |
| Dec 31, 2022 | -115.72 Mn |
| Jun 30, 2022 | 91.62 Mn |
| Jun 30, 2022 | 91.62 Mn |
| Jun 30, 2021 | 41.05 Mn |
| Jun 30, 2021 | 41.05 Mn |